Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Two novel four-drug regimens for tuberculosis showed stronger bacterial clearance than the standard treatment in a phase II trial. The BDMT regimen had a 99% probability of superiority over the standard regimen, while BPMG came in at 83%. Both combinations are advancing to the trial's second stage, potentially fast-tracking the path to phase III testing.
Two investigational four-drug regimens for tuberculosis (TB) are showing real promise against the long-standing standard of care, according to phase II results published in the New England Journal of Medicine. The PARADIGM-4TB adaptive platform trial tested combinations featuring novel agents — ganfeborole and BTZ-043 — alongside established drugs like bedaquiline, moxifloxacin, pretomanid, and delamanid, comparing them to the standard isoniazid-rifampin-pyrazinamide-ethambutol (HRZE) regimen in 401 adults across five countries.
Both new regimens cleared TB bacteria faster than the standard treatment, and the trial's adaptive design is being praised as a smarter way to prioritize which drug combos deserve the time and cost of large phase III trials. Experts note this approach could meaningfully accelerate TB drug development — though they caution that early bacterial clearance doesn't always predict long-term cure.
By the Numbers:
Why it matters: TB remains one of the world's deadliest infectious diseases, and developing better, shorter treatment regimens is a global health priority. This trial's platform design could help researchers move promising drug combinations forward faster — without compromising the rigor needed to confirm real-world benefit.